• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Autonomix Medical Inc.

    9/12/25 5:03:37 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    DEFA14A 1 amix20250911_defa14a.htm FORM DEFA14A amix20240903_defa14a.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     
       

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material Pursuant to §240.14a-12

     

     

    Autonomix Medical, Inc.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.

     

    ☐ Fee paid previously with preliminary materials.

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

         

     

     

     

     

    image04.jpg

     

     

    IMPORTANT NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE AUTONOMIX MEDICAL, INC. ANNUAL STOCKHOLDER MEETING TO BE HELD ON

    OCTOBER 30, 2025 AT 10:00 AM CST

     

     

     

     

     

    VOTING CONTROL CODE: AAAA-BBBB-CCCC-DDDD

     

    Location: at the principal executive offices of Autonomix Medical, Inc. (the "Company") at 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380 and any adjournment or postponement thereof.

     

    This communication provides an overview of the complete proxy materials, including the Proxy Statement and Proxy that are available on the internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy materials are available at:

     

    Meeting Materials:

    https://www.AMIX.vote

     

    To view the proxy materials and vote your shares online:

     

    Step 1: Click the VOTE NOW! button or go to https://my.equitystock.com/voting/login and enter your Voting Control Code provided above.

     

    image05.jpg

     

    Step 2: To view or download the proxy materials, on a mobile device, click the button on the upper left side and select Meeting Documents and click on the document you wish to view. On a computer or tablet, click on the document you wish to view, accessible on the upper right side of the screen. For example, to view or download the Proxy Statement, click on Proxy Statement.

     

    Step 3: To vote online, follow the on-screen instructions. You may vote online until October 29, 2025 at 10:59 PM CST.

     

    To request paper copies of the proxy materials including the proxy card, you must submit a request. There is no charge to you for requesting paper copies. To facilitate timely delivery, please make the request using one of the methods below before October 20, 2025.

     

    image06.jpg
    image07.jpg
    image08.jpg

    PHONE:

    CALL 212-575-5757

    FAX:

    SEND THIS CARD TO (347)-584-3644

    EMAIL:

    FORWARD THIS CARD TO

    [email protected]

     

     

     

     

     

    PROPOSALS

     

     

    The Board of Directors recommend that you vote For on Proposal 1 for the Election of each Director Nominee

     

     

    1.

    To elect 5 Board nominees to the Board of Directors of the Company, each to serve until the 2026 annual meeting of stockholders of the Company or until such person’s successor is qualified and elected.

     

    a. Walter K. Klemp

     

    b. Lori Bisson

     

    c. Jonathan P. Foster

     

    d. David Robins

     

    e. Christopher Capelli

     

     

    The Board of Directors recommend that you vote For on Proposal 2

     

     

    2.

    To ratify the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2026

     

     

    The Board of Directors recommend that you vote For on Proposal 3

     

     

    3.

    To approve an amendment to the Company's amended and restated certificate of incorporation to grant our Board of Directors authority to affect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-2 to 1-for- 25 (or any whole number in between), as determined by the Board in its sole discretion, prior to the one-year anniversary of this Annual Meeting.

     

     

    The Board of Directors recommend that you vote For on Proposal 4

     

     

    4.

    To approve the amended and restated 2023 Equity Incentive Plan.

     

     

    The Board of Directors recommend that you vote For on Proposal 5

     

     

    5.

    To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC.

     

     

     

    The Board of Directors has fixed the close of business on September 8, 2025, as the record date for the determination of shareholders entitled to receive notice of the annual meeting and to vote the company’s Common Stock they held on that date at the meeting or any postponement or adjournment of the meeting.

     

    PLEASE NOTE - THIS IS NOT A PROXY CARD - YOU CANNOT VOTE BY RETURNING THIS CARD. TO VOTE YOUR SHARES, YOU MUST VOTE ONLINE OR REQUEST A PAPER COPY OF PROXY MATERIALS TO RECEIVE A PROXY CARD.

     

    IF YOU WISH TO ATTEND AND VOTE AT THE MEETING, PLEASE BRING THIS NOTICE.

     

    If you encounter any technical difficulties with the virtual meeting platform on the meeting day, please call

    +1-877-804-2062 (TOLL FREE) or email [email protected] Attn: Shareholder Services.

     

     

    YOUR VOTE IS IMPORTANT!

     

     
    Get the next $AMIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment

    Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company's recently announced results from the post hoc analysis of its proof-of-concept human clinical trial ("PoC 1") THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced longer-term post hoc analysis re

    9/4/25 9:00:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

    New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain 100% of responders (n=7) 1 showed zero opioid use at their 3-month post-procedure follow-up2 Quality of life markers further improved including sleep quality, energy level and ability to lead normal daily and leisure time activities and reduced tension, vomiting and constipation THE WOODLANDS, TX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted t

    9/3/25 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

    THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more informa

    9/2/25 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Autonomix Medical Inc.

    DEFA14A - Autonomix Medical, Inc. (0001617867) (Filer)

    9/12/25 5:03:37 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Autonomix Medical Inc.

    DEF 14A - Autonomix Medical, Inc. (0001617867) (Filer)

    9/12/25 4:45:44 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Autonomix Medical Inc.

    424B3 - Autonomix Medical, Inc. (0001617867) (Filer)

    9/11/25 5:01:24 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Hauser Bradley

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:19:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Capelli Christopher

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:16:29 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Klemp Walter V

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:13:57 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    View All

    Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

    Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

    12/19/24 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

    Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

    6/17/24 4:05:00 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Appoints Jennifer Cook as Chief Business Officer

    Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

    3/19/24 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    10/7/24 8:30:24 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care